Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
This study has been completed.
Study NCT01011309   Information provided by Infectious Disease Research Institute

First Received on November 9, 2009.   Last Updated on July 23, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cutaneous Leishmaniasis
Additional conditions recognized in this trial
Leishmaniasis
Leishmaniasis, Cutaneous
More general conditions related to this trial
Euglenozoa Infections
Parasitic Diseases
Protozoan Infections
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Interventions listed in this trial
LEISH-F2 + MPL-SE
Sodium stibogluconate
Additional drug interventions recognized in this trial
Antimony Sodium Gluconate
More general drug interventions related to this trial
Anthelmintics
Anti-Infective Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Pharmacologic Actions
Schistosomicides
Therapeutic Uses
Sponsors listed in this trial
Infectious Disease Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services